Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor GSK1120212 in Subjects With Solid Tumors or Lymphoma

NCT00687622 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00687622
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00687622 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor GSK1120212 in Subjects With Solid Tumors or Lymphoma
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Completed
Start date
July 28, 2008
Completion date
November 8, 2011
Enrollment
206 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumours